Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
"IntroductionDrug targets are the critical link between drugs and their role in the treatment of medical disorders. By grouping drug targets into key protein families, this report provides a comprehensive analysis of the prescription pharmaceutical market by not just molecule type and therapy area, but also by target family.ScopeClassification of the specific drug targets relating to over 650 key products across the PharmaVitae universe Products grouped into major target families, including GPCRs, enzymes, extracellular signalling proteins (ECS), ion channels and nuclear receptors Comprehensive analysis of forecast sales to 2012 by the three fundamental dimensions of pharma space: molecule type, therapy area and target family Discussion of the factors driving the variable performance of different ATC drug classesHighlightsDatamonitor has identified three fundamental dimensions that describe a product's position within the pharma spacemolecule type, therapy area and target type. Analysis of sales across these dimensions reveals key attractiveness characteristics that drive performance The target type acted on by a product dictates its standing against these key characteristics. Products acting on ECS targets tend to rate most highly and will outperform those acting on other target types. Conversely, products addressing ion channels or nuclear receptors rate poorly and face an overall decline across 200612 The arrival of monoclonal antibody and therapeutic protein technologies allowed ECS targets to be exploited, expanding the 'druggable' target space and driving sales growth across 200612. Beyond 2012, further technological revolutions will, however, be required if the success experienced by these product classes is to be repeatedReasons to PurchaseIdentify product positioning not just in terms of molecule type and therapy area, but also according to target family Rate marketed and pipeline products against the three attractiveness characteristics that determine a product's likelihood of commercial success Understand the challenges faced by different product groups depending on the targets that they address"
23-Oct-07 Format: PDF Pages: 194
Table of Contents
Price: $7,600.00 / GBP3,800.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.